KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Arbutus Biopharma (ABUS) over the last 15 years, with Q3 2025 value amounting to -$10.0 million.

  • Arbutus Biopharma's Cash from Investing Activities rose 1641.08% to -$10.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.4 million, marking a year-over-year decrease of 443.93%. This contributed to the annual value of $22.9 million for FY2024, which is 5480.27% down from last year.
  • Arbutus Biopharma's Cash from Investing Activities amounted to -$10.0 million in Q3 2025, which was up 1641.08% from $15.6 million recorded in Q2 2025.
  • In the past 5 years, Arbutus Biopharma's Cash from Investing Activities registered a high of $22.2 million during Q4 2023, and its lowest value of -$60.1 million during Q1 2022.
  • For the 5-year period, Arbutus Biopharma's Cash from Investing Activities averaged around $160105.3, with its median value being $10.4 million (2023).
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first surged by 85889.21% in 2021, then tumbled by 42959.77% in 2022.
  • Over the past 5 years, Arbutus Biopharma's Cash from Investing Activities (Quarter) stood at -$8.1 million in 2021, then surged by 256.16% to $12.7 million in 2022, then soared by 75.25% to $22.2 million in 2023, then plummeted by 39.66% to $13.4 million in 2024, then tumbled by 174.71% to -$10.0 million in 2025.
  • Its Cash from Investing Activities stands at -$10.0 million for Q3 2025, versus $15.6 million for Q2 2025 and $11.3 million for Q1 2025.